Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act

International Public Goods and Transfer of Technology Under a Globalized Intellectual Property Regime

Volumn , Issue , 2005, Pages 457-480

  Grabowski, Henry ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 20044379651     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511494529.023     Document Type: Chapter

References (49)

1. Michael Kremer, Pharmaceuticals and the Developing World, 16 J. ECON. PERSP. 67 (2002).
2. Joe DiMasi et al., The Price of Innovation: New Estimates of Drug Development Costs, 22 J. HEALTH ECON. 151 (2003).
3. F.M. Scherer, The Link Between Gross Profitability and Pharmaceutical R&D Spendings, 20 HEALTH AFF. 216 (2001);
4. Henry Grabowski et al., Returns on Research and Development for 1990s New Drug Introductions, 20 PHARMACOECON. 11 (2002).
5. Pharmaceutical Research and Manufacturers of America, Pharmaceutical Industry Profile 2003, at 3 (PhRMA 2003).
6. Joe DiMasi et al., above n. 7, at 165.
7. F.M. SCHERER, NEW PERSPECTIVES ON ECONOMIC GROWTH AND TECHNOLOGICAL INNOVATION 71–80 (Brookings Institution Press 1999).
8. Grabowski et al., above n. 7, at 23–28.
9. Henry Grabowski & John Vernon, The Distribution of Sales Revenues from Pharmaceutical Innovation, 18 PHARMACOECON. 21 (2000).
10. Henry Grabowski & John Vernon, The Determinants of R&D Expenditures in the Pharmaceutical Industry, in DRUGS AND HEALTH (R. Helms ed., AEI 1981).
11. Henry Grabowski & John Vernon, The Determinants of Pharmaceutical Research and Development Expenditures, 10 J. EVOLUTIONARY ECON. 201 (2000).
12. F.M. Scherer, The Link Between Gross Profitability and Pharmaceutical R&D Spendings, 20 HEALTH AFF. 216 (2001).
13. Richard D. Levin et al., Appropriating the Returns from Industrial Research and Development, 3 BROOKINGS PAPERS ON ECON. ACTIVITY 783 (1987).
14. Edwin Mansfield, Patents and Innovation: An Empirical Study, 32 MGMT. SC I. 173 (1986).
15. Wes Cohen et al., Appropriability Conditions and Why Firms Patent and Why They Do Not in the American Manufacturing Sector, Carnegie-Mellon University Working Paper (1997).
16. F.M. SCHERER, INDUSTRY STRUCTURE, STRATEGY AND PUBL IC POLICY 361–362 (Harper Collins 1996).
17. Henry Grabowski, Innovation and International Competitiveness in Pharmaceuticals, in EVOLVING TECHNOLOGY AND MARKET STRUCTURE 167. Arnold Heertje & Mark Perlman eds., University of Michigan Press 1990.
18. Robert E. Evenson & Sunil Kanwar, Does Intellectual Property Protection Spur Technological Change?, Yale Economics Growth Center Discussion Paper No. 831 (2001).
19. Ian Neary, Japanese Industrial Policy and the Pharmaceutical Industry, in INDUSTRI A L POLICY AND THE PHARMACEUTICAL INDUSTRY 12 (Adrian Toswe ed., OHE 1995).
20. Food and Drug Modernization Act of 1997, Pub. L. 105–115, 111 Stat. 2296 (1997) [hereinafter FDAMA].
21. Sheila R. Schulman et al., Implementation of the Orphan Drug Act: 1983–1992, 47 FOOD & DRUG L.J. 363 (1992).
22. Sheila R. Schulman & Michael Manocchia, The U.S. Orphan Drug Programme 1983–1995, PHARMACOECONOMICS 313 (1997).
23. Willis Emmons & Ashok Nimgade, Burroughs Wellcome and AZT, Case 9–792–004, Harvard Business School (1991).
24. Hannah E. Kettler, Narrowing the Gap Between Provision and Need for Medicines in Developing Countries (Office of Health Economics 2000).
25. www.fda.gov/orphan/history.htm.
26. www.fda.gov/orphan/designat/allap.rtf.
27. Sheila R. Schulman & Jeffrey Brown, The Food and Drug Administration’s Early Access and Fast-Track Approval Initiatives: How Have They Worked?, 50 FOOD & DRUG L.J. 503 (1995);
28. Christopher Paul Milne, Fast Track Designation Under the Food and Drug Modernization Act: The Industry Experience, 35 DRUG I NFO. J. 71 (2001).
29. Janice M. Reichert, Clinical Development of Therapeutic Medicines: A Biopharmaceutical
30. Versus Pharmaceutical Product Comparison, 35 DRUG INFO. J. 337 (2001).
31. James Love, What Do U.S. IRS Tax Returns Tell Us About R&D Investment?, Consumer Project on Technology Presentation (16 Jan. 2003) (citing data and analysis provided by T. Balasubramaniam), available at www.cptech.org.
32. International Classification of Diseases, Ninth Revision (1996), available at www.cdc.gov/NCHS/icd9.htm.
33. CDER Report to the Nation for the years 2000 to 2003, at www.fda.gov/cder/reports.
34. The sources for Table 1 are FDA, Office of Orphan Products Development, website: http://www.fda/gov/orphan (last visited 1 July 2003).
35. Christopher-Paul Milne, Orphan Products – Pain Relief for Clinical Development Headaches, NATURE BIOTECHNOLOGY, 20 Aug. 2002, at 780.
36. Keith E. Maskus, Ensuring Access to Essential Medicines: Some Economic Considerations, 20 WI S. INT’ L L.J., 563 (2002).
37. James Russo, Executive Director of the Partnership for Quality Medical Donations, available at www.pmq.org.
38. Peter Wehrwein, Pharmacophilanthropy, Harvard University (1993), available at http://www.hsph.harvard.edu/review/summer_pharmaco.shtml.
39. www.iavi.org/pdf/ipagreements.pdf.
40. www.tballiance.org;
41. Aimee Dingswell, Chiron: Parsing the TB Universe, BIOCENTURY, Feb. 2002.
42. Chris Milne et al., Orphan Drug Laws in Europe and the U.S.: Incentives for the Research and Development of Medicines for the Diseases of Poverty, WHO Commission on Macroeconomics and Health Working Paper No. WG 2:9, at 6 (2002), available at http://www.cmhealth.org/docs/wg2_paper9.pdf.
43. MICROBIAL THREATS TO HEALTH: EMERGENCE, DETECTION, AND RESPONSE 184 (Mark S. Smolinski et al. eds., National Academies Press 2002) (discussing these new technologies).
44. World Health Organization, World Health (2002), available at www.who.int/genomics.
45. Would Prescription Drug Importation Reduce U.S. Drug Spending?, Congressional Budget Office Economic and Budget Issue Brief (29 Apr. 2004).
46. Ceci Connolly, DrugReimportationPlanSavesCity$2.5Million, WASH. POST, 15 July 2004, atA03.
47. Michael Kremer & Jeffrey Sachs, A Cure for Indifference, THE FINANCIAL TIMES, May 1999, at 14.
48. Michael Kremer, Creating Markets for New Vaccines – Part I: Rationale, and Part II: Design
49. Issues, in INNOVATION POLICY AND THE ECONOMY (Adam B. Jaffe et al. eds., 2001).